Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05306574 · ClinicalTrials.gov registry record · Phase 3
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
A Phase 3 study, sponsored by Vor Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT05306574 is a Phase 3 study that was terminated before completion, run by Vor Biopharma. The registered enrollment target is 91 participants.
The verdict
NCT05306574, a Phase 3 study, was terminated before completion, sponsored by Vor Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Telitacicept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2025-01-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05306574
The ClinicalTrials.gov registry entry for NCT05306574 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vor Biopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05306574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05306574 about?
NCT05306574 is a clinical study titled "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)". The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
What is the current status of trial NCT05306574?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2022-06-20. Estimated completion is 2025-01-06.
What interventions are being tested in trial NCT05306574?
The interventions under investigation include: Placebo (BIOLOGICAL), Telitacicept (BIOLOGICAL).
Who is sponsoring clinical trial NCT05306574?
This trial is sponsored by Vor Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.